— Know what they know.
Not Investment Advice

PROK

ProKidney Corp.
1W: -12.0% 1M: -18.3% 3M: -25.6% YTD: -17.9% 1Y: +79.4% 3Y: -81.5%
$1.83
+0.04 (+2.23%)
After Hours: $1.71 (-0.12, -6.28%)
NASDAQ · Healthcare · Biotechnology · $529.8M · Alpha Radar Neutral · Power 46
Smart Money Score
Bullish 75
Insider+$10.3M
Congress
ETF Holdings
Key Statistics
Market Cap$529.8M
52W Range0.46-7.13
Volume810,608
Avg Volume847,120
Beta1.80
Dividend
Analyst Ratings
5 Buy 1 Hold 1 Sell
Consensus Buy
Company Info
CEOBruce Culleton
Employees204
SectorHealthcare
IndustryBiotechnology
IPO Date2021-06-30
2000 Frontis Plaza Blvd.
Winston-Salem, NC 27103
US
336 999 7028
About ProKidney Corp.

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Recent Insider Trades

NameTypeSharesPriceDate
Coulston James A-Award 600,000 $2.24 2026-03-01
Weber Darin J. A-Award 400,000 $2.24 2026-03-01
Girolamo Todd C A-Award 600,000 $2.24 2026-03-01
Culleton Bruce A-Award 3,000,000 $2.24 2026-03-01
Pereira Brian JG S-Sale 54,333 $2.37 2025-11-13

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms